peginterferon-alfa-2a
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Vertex Pharmaceuticals Incorporated
Conditions
Chronic Hepatitis C VirusChronic Hepatitis C Virus InfectionHIV InfectionsHepatitis BHepatitis C
Phase 2
Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
WithdrawnNCT00051077
Updated: 2021-11-01
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
TerminatedNCT01080222
Start: 2010-08-31End: 2013-11-30Updated: 2020-09-30
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
CompletedNCT01516918
Start: 2012-02-29End: 2013-12-31Updated: 2014-10-20